Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. releases the March 2026 Securities Movement Monthly Report

Zhongfang Network Data
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. submitted the monthly securities change report as of March 31, 2026, to The Stock Exchange of Hong Kong Limited on April 1, 2026.
The report shows that during the reporting period, the company’s legal capital, issued shares, and treasury shares remained unchanged.

According to the report, the company’s total legal capital is RMB 1,625,790,949, consisting of H-shares and A-shares.
Among them, the legal capital of H-shares listed on the Hong Kong Stock Exchange is RMB 219,900,000, corresponding to 219,900,000 shares, with a par value of RMB 1 per share.
The legal capital of A-shares listed on the Shanghai Stock Exchange is RMB 1,405,890,949, corresponding to 1,405,890,949 shares, with a par value also of RMB 1 per share.
The legal capital of both share classes remained unchanged this month.

Regarding issued shares, as of March 31, 2026, the total issued H-shares are 219,900,000 shares, with no treasury shares;
The total issued A-shares are 1,405,890,949 shares, also with no treasury shares.
The number of issued shares for both classes remained consistent with the end-of-last-month figures, with no issuance, repurchase, cancellation, or treasury share changes during this month.

The company also confirms that its H-share class complies with the public float requirements applicable under the Listing Rules of The Stock Exchange of Hong Kong Limited.
According to the rules, the minimum public float threshold for Chinese issuers with other listed shares is 5% of the total issued shares (excluding treasury shares) of the H-share class.

Additionally, the company confirms that during this reporting month, no issuance of shares was made under share option plans, warrants, convertible bonds, or other contractual arrangements for issuing shares.
The board of directors also confirms that, to the best of its knowledge and belief, all securities issuance or treasury share changes (if any) during the reporting period have been formally authorized and complied with all applicable listing rules and laws and regulations.